2020年美国风湿病学会痛风管理指南
采用GRADE方法系统评价证据并经共识流程形成推荐。
要点
- 痛风石、影像学损伤或频繁发作者强推荐启动ULT,别嘌醇为一线首选。
- 别嘌醇起始剂量≤100 mg/日(CKD更低),非布司他<40 mg/日,采用达标治疗策略,SU目标<6 mg/dl。
- 启动ULT时强推荐至少3-6个月抗炎预防;急性发作强推荐秋水仙碱、NSAIDs或糖皮质激素。
核心结论
- 该指南基于GRADE方法及共识流程,为痛风管理提供方向性推荐。
研究设计与样本
- 制定机构为美国风湿病学会(ACR),采用GRADE方法系统评价证据并结合患者输入与共识流程形成推荐。
关键数值与推荐
- 强推荐所有痛风石、痛风所致影像学损伤或频繁痛风发作的患者启动ULT。
- 强推荐别嘌醇作为首选一线ULT,包括中重度慢性肾脏病(CKD;分期>3)患者。
- 强推荐别嘌醇起始剂量≤100 mg/日(CKD患者更低)或非布司他<40 mg/日。
- 强推荐达标治疗策略,依据系列血尿酸(SU)测量调整ULT剂量,SU目标<6 mg/dl。
- 启动ULT时强推荐联用抗炎预防治疗至少3-6个月。
临床怎么用
- 临床可根据患者痛风石、影像学损伤或发作频率决定是否启动ULT,并首选别嘌醇。
- 起始ULT时采用低剂量并联合抗炎预防至少3-6个月,按SU目标<6 mg/dl调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide guidance for the management of gout, including indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations. METHODS: Fifty-seven population, intervention, comparator, and outcomes questions were developed, followed by a systematic literature review, including network meta-analyses with ratings of the available evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group consensus process was used to compose the final recommendations and grade their strength as strong or conditional. RESULTS: Forty-two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat (<40 mg/day); and a treat-to-target management strategy with ULT dose titration guided by serial serum urate (SU) measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for a duration of at least 3-6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended. CONCLUSION: Using GRADE methodology and informed by a consensus process based on evidence from the current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions on the management of gout.
引用
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020. PMID: 32391934. doi:10.1002/acr.24180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。